Extracorporeal membrane oxygenation (ECMO) is a refractory treatment for acute respiratory distress syndrome (ARDS) due to influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, also referred to as coronavirus disease 2019 [COVID-19]). We conducted this study to compare the outcomes of influenza patients treated with veno-venous-ECMO (VV-ECMO) to COVID-19 patients treated with VV-ECMO, during the first wave of COVID-19.

中文翻译：

---

第一波 COVID-19 期间流感与 COVID-19 体外膜氧合的结果

体外膜肺氧合 (ECMO) 是一种难治性治疗方法，用于治疗由流感和严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2，也称为 2019 冠状病毒病 [COVID-19]) 引起的急性呼吸窘迫综合征 (ARDS)。我们进行了这项研究，以比较在第一波 COVID-19 期间接受静脉-静脉-ECMO (VV-ECMO) 治疗的流感患者与接受 VV-ECMO 治疗的 COVID-19 患者的结果。